Genfit SA (GNFT) has released an update.
GENFIT SA reported strong first half-year 2024 financial results, with €61.6 million in cash reserves and €59.0 million in revenue, bolstered by a €48.7 million milestone from U.S. sales of its PBC treatment, Iqirvo. The company anticipates additional European momentum with an expected €26.5 million milestone following Iqirvo’s anticipated pricing and reimbursement approval. GENFIT’s advancements in liver disease treatments and diagnostics, alongside positive U.S. market reception, position it optimistically for future developments.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
